EUVIMEDEUVIMED entdecken
Crossref

3D layered co-culture model enhances Trastuzumab Deruxtecan sensitivity and reveals the combined effect with G007-LK in HER2-positive non-small cell lung cancer

Akari Shiraishi, Tomoko Oh-Hara, Yuki Takahashi, Ken Uchibori, Makoto Nishio, Ryohei Katayama

Biochemical and Biophysical Research Communications · 2024

DOI: 10.1016/j.bbrc.2024.150255 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biochemical and Biophysical Research Communications, 2024. Verfasst von Akari Shiraishi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Div of Experimental Chemotherapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, 3-8-31, Ariake, Koto-ku, Tokyo, 135-8550, Japa…. Hauptthemen laut MEDLINE: Trastuzumab, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Immunoconjugates. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: Kobayashi Foundation for Cancer Research, Japan Society for the Promotion of Science, Ministry of Education, Culture, Sports, Science and Technology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Human epidermal growth factor receptor 2 (HER2) aberrations are observed in various cancers. In non-small cell lung cancer, genetic alterations activating HER2, mostly exon 20 insertion mutations, occur in approximately 2-4% of cases. Trastuzumab deruxtecan (T-DXd), a HER2-targeted antibody-drug conjugate has been approved as the first HER2-targeted drug for HER2-mutant lung cancer. However, some cases are not responsive to T-DXd and the primary resistant mechanism remains unclear. In this study, we assessed sensitivity to T-DXd in JFCR-007, a patient-derived HER2-mutant lung cancer cell line. Although JFCR-007 was sensitive to HER2 tyrosine kinase inhibitors, it showed resistance to T-DXd in attachment or spheroid conditions. Accordingly, we established a three-dimensional (3D) layered co-culture model of JFCR-007, where it exhibited a lumen-like structure and became sensitive to T-DXd. In addition, an in-house inhibitor library screening revealed that G007-LK, a tankyrase inhibitor, was effective when combined with T-DXd. G007-LK increased the cytotoxicity of topoisomerase-I inhibitor, DXd, a payload of T-DXd and SN-38. This combined effect was also observed in H2170, an HER2-amplified lung cancer cell line. These results suggest that the proposed 3D co-culture system may help in evaluating the efficacy of T-DXd and may recapitulate the tumor microenvironment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TrastuzumabCarcinoma, Non-Small-Cell LungLung NeoplasmsImmunoconjugatesErb-b2 Receptor Tyrosine KinasesCoculture TechniquesHumansCell Line, TumorDrug Resistance, NeoplasmCrown EthersAntineoplastic Agents, ImmunologicalCamptothecin

Stichwörter der Autor:innen

3D co-culture systemG007-LKHER2NSCLCTrastuzumab deruxtecan (T-DXd)

Substanzen

TrastuzumabImmunoconjugatesErb-b2 Receptor Tyrosine KinasesCrown EthersAntineoplastic Agents, ImmunologicalCamptothecintrastuzumab deruxtecanERBB2 protein, human

Autor:innen und Institutionen

  • Div of Experimental Chemotherapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, 3-8-31, Ariake, Koto-ku, Tokyo, 135-8550, Japan; Department of Computational Biology and Medical Sciences, Graduate…
  • Div of Experimental Chemotherapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, 3-8-31, Ariake, Koto-ku, Tokyo, 135-8550, Japan.
  • Technical Research Institute, TOPPAN Holdings Inc., Japan; Division of Clinical Chemotherapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, 3-8-31, Ariake, Koto-ku, Tokyo, 135-8550, Japan.
  • Div of Experimental Chemotherapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, 3-8-31, Ariake, Koto-ku, Tokyo, 135-8550, Japan; Department of Thoracic Medical Oncology, The Cancer Institute Hospi…
  • Department of Thoracic Medical Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.

Förderung

  • Kobayashi Foundation for Cancer Research
  • Japan Society for the Promotion of Science
  • Ministry of Education, Culture, Sports, Science and Technology
  • Japan Science and Technology Agency
  • Japan Agency for Medical Research and Development
  • Takeda Science Foundation
  • Nakatomi Foundation
  • Nippon Foundation

Zitieren

APA

Shiraishi, A., Oh-Hara, T., Takahashi, Y., Uchibori, K., Nishio, M., & Katayama, R. (2024). 3D layered co-culture model enhances Trastuzumab Deruxtecan sensitivity and reveals the combined effect with G007-LK in HER2-positive non-small cell lung cancer. Biochemical and Biophysical Research Communications. https://doi.org/10.1016/j.bbrc.2024.150255

Vancouver

Shiraishi A, Oh-Hara T, Takahashi Y, Uchibori K, Nishio M, Katayama R. 3D layered co-culture model enhances Trastuzumab Deruxtecan sensitivity and reveals the combined effect with G007-LK in HER2-positive non-small cell lung cancer. Biochemical and Biophysical Research Communications. 2024. doi:10.1016/j.bbrc.2024.150255

BibTeX
@article{Shiraishi2024,
  author = {Shiraishi, Akari and Oh-Hara, Tomoko and Takahashi, Yuki and Uchibori, Ken and Nishio, Makoto and Katayama, Ryohei},
  title = {3D layered co-culture model enhances Trastuzumab Deruxtecan sensitivity and reveals the combined effect with G007-LK in HER2-positive non-small cell lung cancer},
  journal = {Biochemical and Biophysical Research Communications},
  year = {2024},
  doi = {10.1016/j.bbrc.2024.150255}
}
Kostenlos starten →